To investigate if NCL could be a therapeutic target in pre-B ALL, we treated leukemia cells with a widely-studied NCL-specific aptamer AS1411 and control CRO2632,40. This evidence concerns the gene NUCLEOLIN and acute lymphoblastic leukemia.